Solventum Corp. (SOLV)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Solventum Corp..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 85.40 $ — 88% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 0.8% failed
- More than 10% revenue growth is expected for the coming year 3.5% failed
- Share count grows by less than 3% a year 0.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 0.7% failed
- Gross margin at 40% or higher and without meaningful erosion 53.5% failed
- Goodwill from acquisitions does not grow faster than revenue 39.9% passed
- Net debt below twice EBITDA 1.6 x EBITDA passed
- Operating cash flow covers the profits of the last three years 88 m passed
- Return on capital at 15% or higher, or up versus two years ago 19.6% passed
- Insiders hold at least 10% or are net buyers 15.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.8% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6.55 | 6.34 – 6.60 | 8,194 | 7.2% | 15 |
| 12/31/2027 | 7.09 | 6.69 – 7.32 | 8,479 | 8.2% | 15 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.91 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.18 | -88.70 | 2,075 | 1.90 | 1.50 | 219 | 92 |
| 2025: Q1 | 0.78 | -42.90 | 2,070 | 2.70 | 6.60 | 29 | -80 |
| 2025: Q2 | 0.51 | 0.10 | 2,161 | 3.80 | 4.20 | 169 | 59 |
| 2025: Q3 | 7.22 | 928.80 | 2,096 | 0.70 | 60.40 | 76 | -21 |
| 2025: Q4 | 0.36 | 102.30 | 1,998 | -3.70 | 3.20 | 95 | 32 |
| 2026: Q1 | 0.07 | -90.50 | 2,007 | -3.00 | 0.60 | -189 | -273 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2020 | 7,281 | 1,430 | 1,138 | 6.60 | 2,026 | – | – |
| 2021 | 8,171 | 1,879 | 1,460 | 8.47 | 2,202 | 12,059 | 14,075 |
| 2022 | 8,130 | 1,693 | 1,343 | 7.79 | 1,679 | 11,742 | 13,594 |
| 2023 | 8,197 | 1,692 | 1,346 | 7.79 | 1,915 | 11,666 | 13,943 |
| 2024 | 8,254 | 1,036 | 479 | 2.76 | 1,185 | 2,959 | 14,457 |
| 2025 | 8,325 | 2,181 | 1,556 | 8.88 | 369 | 5,049 | 14,294 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Solventum Corporation ist ein Gesundheitsunternehmen, das ein Portfolio von Lösungen zur Deckung kritischer Kunden- und Patientenbedürfnisse in den USA und international entwickelt, fertigt und kommerzialisiert. Es ist in drei Segmenten tätig: Medsurg, Dental Solutions und Health Information Systems.
| Employees | 20,584 |
|---|---|
| Headquarters | Eagan, MN |
| Address | 1750 Yankee Doodle Road, 55121 Eagan, United States |
| Phone | (651) 733-1110 |
| Website | solventum.com |
| IPO Date | 26. Mar 2024 |
| ISIN | US83444M1018 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Bryan C. Hanson | CEO & Director | 1967 |
| Wayde D. McMillan | Executive VP & CFO | 1970 |
| Amy Landucci | Chief Information & Digital Officer | 1975 |
| Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 1967 |
| Heather L. Knight | Chief Commercial Officer | 1972 |
| Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | – |
| Kate Dobbs | Chief Communications & Corporate Marketing Officer | – |
| Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 1970 |
| Tammy L. Gomez | Chief Human Resources Officer | 1973 |
| Paul S. Harrington | Chief Supply Chain Officer | 1970 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.